but was not affected by addition of ß1 integrin antibody (Fig. 6d). By contrast, a neutralizing antibody specific for VEGF receptor 2 (VEGFR2) did not affect lactadherin-induced AKT ...

More recently, ivonescimab, a bsAb targeting PD-1 and vascular endothelial growth factor (VEGF), was tested compared with pembrolizumab in the phase III HARMONi-2 trial for patients with advanced ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn ...

One of the most recent agents to enter phase 1 clinical trials, combretastatin A-4 phosphate (CA4P), represents a new class of antiangiogenic compounds that act by inducing apoptosis in target ...

Previous studies have shown that α9-integrin expression and activation in mature dorsal root ganglion neurons enable the regeneration of injured axons within the spinal cord. However, tissue ...

2022). While this “vascular shutdown” effectively starves tumors, surviving hypoxic cells at the tumor periphery often upregulate pro-angiogenic factors (e.g., VEGF, HIF-1α) and adopt aggressive ...

Stay up to date on practice-changing data in community practice.

Patients were treated with anti-vascular endothelial growth factors (VEGF) on pro re nata protocol, photodynamic therapy, laser photocoagulation or a combination. Main outcome measures were change in ...

Cancer Res (2025) 85 (8_Supplement_1): 69.